CancerNetwork®

🚨 The incidence of breast and colorectal cancer is rising among patients 50 years and younger Our latest feature "The Rise of Early-Onset Cancers: Investigating Breast and CRC Occurrences" discusses what that means for oncology. ⬇️ Check it out now ⬇️ hubs.li/Q04983MV0 #bcsm #crcsm #Oncology

🎙️ This week's episode of Oncology Decoded is here! Our hosts, @mkbupathi and @BGarmezy, spoke with this week's guests, @UroBiehn and @MarkTysonMD, about non–muscle-invasive bladder cancer treatment! Tune in here, Spotify, Apple Podcasts, and more to listen! cancernetwork.com/view/optimizin… #blcsm #NMIBC #oncology

🚨 The FDA has approved atezolizumab, as well as atezolizumab and hyaluronidase-tqjs for the adjuvant treatment of MIBC after cystectomy in those with ctDNA MRD. hubs.li/Q04gQh_n0 #blcsm #MIBC #bladdercancer #oncology | @FDAOncology

Use of an evidence-based practice for saline flushes led to a reduction in AEs and financial toxicity vs traditional heparin in patients with cancer. ⬇️ Read more about the practice here ⬇️ hubs.li/Q04gHDT40 #oncology #cancer #ONS26

Patients with low-grade intermediate-risk NMIBC who were treated with mitomycin experienced sustained 36-month responses. 💠 36-month DOR rate: 64.5% hubs.ly/Q04gBGPK0 #blcsm #bladdercancer #oncology

Six major journals, but only three can stay. 📚 Watch as @BalazsHalmosMD takes on "Keep 3, Cut 3," making the hard calls between NEJM, JAMA, and more. 🏥 Do you agree with his top picks? Watch more here: youtube.com/watch?v=YlpEaJ…

🧘‍♂️ New research in @FutureOncology: 8 weeks of Mindfulness-Based Stress Reduction significantly eases chemo distress in patients with colorectal cancer. Headline Findings: 📉 Sig. reduction in CINV severity (p<0.001) 📉 Lower anxiety & depression scores 📈 Benefits increased over treatment cycles 🛡️ Safe, non-pharmacological adjuvant #crcsm #Oncology #ColorectalCancer

For patients with metastatic melanoma who do not respond to initial immunotherapy, clinical options have historically been bleak; however, TILs may be changing the prognosis. 🎥 Listen to Muhammad Umair Mushtaq, MD's, thoughts on this ⬇️ hubs.li/Q04gx6Bh0 #melsm #melanoma #oncology | @mumairmushtaq

Investigators are currently evaluating emiltatug ledadotin among patients with different solid tumors in a phase 1 trial. hubs.li/Q04gwzRG0 #oncology #cancer

The HPK1 inhibitor NDI-101150 achieved “impressive” single-agent activity and a manageable safety profile in advanced solid tumors, including ccRCC. In the ccRCC population (n = 22): 💠 3 responses 💠 54.5% disease control 💠 14% Grade ≥3 TRAEs hubs.li/Q04glj980 #kcsm #RCC #oncology #cancer

🚨 The FDA approved oral decitabine and cedazuridine tablets with venetoclax for newly diagnosed AML in adults ≥75 years, or who have comorbidities that preclude the use of intensive induction chemotherapy. hubs.ly/Q04gprcV0 #leusm #AML #leukemia #oncology | @FDAOncology

🚨 The FDA has granted accelerated approval to sonrotoclax for R/R mantle cell lymphoma after at least 2 lines of systemic therapy, including a BTK inhibitor. cancernetwork.com/view/fda-appro… #lymsm #MCL #lymphoma #oncology | @FDAOncology

Class is in session 🎓 Join MDs Luciano Costa, Muhamed Baljevic, and Carol Ann Huff in this CancerNetwork® Training Academy video on BCMA-directed bispecific antibodies in early relapse multiple myeloma. Watch now: hubs.li/Q04cLkNq0 #TrainingAcademy #MultipleMyeloma #Oncology

"The main, or the overriding clinical need in PTCL or T-cell lymphomas is simply more effective therapies." – Steven M. Horwitz, MD ⬇️ Horwitz breaks down the utility of duvelisib in PTCL ⬇️ hubs.li/Q04gkBQ90 #lymsm #lymphoma #oncology #cancer

💉 The GNOS-PVO1 showed promise in MGMT unmethylated glioblastoma! "This kind of vaccine is a first for glioblastoma..." – lead study author Tanner M. Johanns, MD, PhD (@SitemanCenter) #btsm #glioblastoma #oncology

📈 Zoldonrasib delivered "promising" activity and a "superb" safety profile in KRAS G12D+ NSCLC. We spoke with Jonathan Wesley Riess, MD, MS, about these findings! Read it here ➡️ hubs.li/Q04glFVB0 #lcsm #NSCLC #lungcancer #oncology | @riess_md

INBRX-106 plus PD-1 conferred a higher response rate vs PD-1 monotherapy as a first-line therapy for patients with HNSCC, according to interim findings from a phase 2 trial. 💪 44.0% vs 21.4% ORR 🎯 3 confirmed responses with INBRX-106 🩺 Manageable safety #hncsm #oncology

The FDA has granted RMAT designation to RZ-001, an adenovirus-mediated trans-splicing ribozyme targeting and replacing hTERT mRNA, for the treatment of patients with HCC. ⬇️ Read more here ⬇️ hubs.li/Q04g9l7B0 #HCC #hpbcsm #oncology #cancer

🥊Final round: The real-world side of CAR T In this final Face Off episode, experts debate how work, caregiving, and access challenges impact treatment decisions for relapsed DLBCL patients. Watch now! hubs.li/Q04f3Wf40 #Oncology #FaceOff #CAR_T #CancerNetwork

The future of immune effector cell therapy is being written right now. 📝 From mitigating toxicities to expanding beyond hematologic malignancies, what does the road ahead look like for immune-based treatments? Tune in to our latest podcast for expert insights on the next decade of cell therapy. 🎧 Listen here: hubs.li/Q04g9v2k0 #oncology #cancer #celltherapy #Immunotherapy | @kczmj